Pfizer Inc. (NYSE:PFE), a multinational pharmaceutical industry company, has garnered investor interest after management reaffirmed its annual revenue and earnings forecast from October. The company’s strong performance in the third quarter of 2024, with a 32% increase in revenue, has bolstered its financial stability.
With a dividend yield of 6.47%, Pfizer Inc. (NYSE:PFE) offers an attractive entry point for investors seeking reliable income. The company’s Oncology portfolio showed strong performance, driven by key products like Padcev, Xtandi, Lorbrena, and Braftovi/Mektovi. Moreover, Pfizer has successfully addressed the heightened demand for Paxlovid during the recent surge in COVID-19 cases.
As of Q3 2024, 80 hedge funds owned stakes in Pfizer Inc. (NYSE:PFE), worth over $3 billion collectively. The company’s leading stakeholder, Two Sigma Advisors, held nearly 17 million shares.
Pfizer Inc. (NYSE:PFE) remains a top choice for investors seeking dividend growth stocks that offer consistent yields and protect against market declines. With its strong cash position and significant increase in revenue, the stock is poised to deliver attractive returns in the coming year.
Key Highlights:
– Pfizer Inc. (NYSE:PFE) has a 6.47% dividend yield.
– The company reported a 32% increase in revenue in Q3 2024.
– 80 hedge funds owned stakes in Pfizer Inc. (NYSE:PFE), worth over $3 billion collectively.
– Two Sigma Advisors held nearly 17 million shares of the stock.
Note: The article has been simplified and reformatted to provide essential information about Pfizer Inc. (NYSE:PFE) as a top January dividend stock to buy, while retaining key highlights from the original text.
Source: https://finance.yahoo.com/news/pfizer-inc-nyse-pfe-best-145916604.html